ArticleCell reports2022
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.
0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
13.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 127 citations in OpenAlex.
- PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma.Oncoimmunology · 2026Article
- ATR inhibition induces NF-κB-dependent immunogenicity in Merkel cell carcinoma independent of cGAS-STING.NPJ precision oncology · 2026Article
- Article
- MDM2 binds and suppresses RNA polymerase III to restrain the innate immune response to cytosolic DNA.Cell death and differentiation · 2026Article
- Article
- Systematic analyses to explore kinase gene set-based signature in glioma, in which WEE1 contributes to tumor progression.Discover oncology · 2026Article
- cGAS-STING pathway in lung cancer and emerging therapeutic approaches.Drug discovery today · 2026Review
- A feedback mechanism from prostate cancer cells to macrophages, reinforced by STAT1, regulates tumor progression and resistance to radiotherapy.Cell death & disease · 2026Article
- Therapeutic scheduling of WEE1 inhibition preserves T cell function and promotes immune control of HPVbioRxiv : the preprint server for biology · 2026Article
- Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC.Nature communications · 2026Article
- Activation of stimulator of interferon genes (STING) and inhibition of vascular endothelial growth factor receptor (VEGFR) by telatinib induce antitumor activity.The Journal of biological chemistry · 2026Article
- Novel therapeutic potential of the PARP inhibitor talazoparib in synovial sarcoma and its combined effect with ATR inhibitor.Discover oncology · 2026Article
- Immunotherapy and the novel therapeutic development for small-cell lung cancer.Therapeutic advances in medical oncology · 2026Review
- Inducing tumor-intrinsic innate immune response to break cancer immunotherapy resistance.Frontiers in medicine · 2026Review
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
- Advancing small cell lung cancer metastasis research: innovations in preclinical mouse models.Cancer metastasis reviews · 2025Review
- Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities.International journal of molecular sciences · 2025Review
- Genome instability and crosstalk with the immune response.Genome medicine · 2025Review
- Enhancing anti-tumor immunity by targeting BATF and the STAT1/PD-L1 pathway in cervical carcinoma.Cellular and molecular life sciences : CMLS · 2025Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 2 countries.
Hirokazu TaniguchiDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Rebecca CaeserDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Shweta S ChavanMarie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Yingqian A ZhanCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Andrew ChowDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Parvathy ManojDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Fathema UddinDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Hidenori KitaiProgram in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Rui QuAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Omar HayattAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Nisargbhai S ShahDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Álvaro Quintanal VillalongaDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Viola AllajDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA.
Evelyn M NguyenDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA; Cancer Biology Program, Louis V. Gerstner Jr. Graduate School of Biomedical Sciences, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Joseph ChanDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA; Program for Computational and Systems Biology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Adam O MichelDrug Safety and Pharmacometrics, Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA; Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hiroshi MukaeDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, 852-8501, Japan.
Elisa de StanchinaAntitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Charles M RudinDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA; Program in Molecular Pharmacology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: rudinc@mskcc.org.
Triparna SenDepartment of Medicine, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, Mortimer B. Zuckerman Research Center, Office: Z1701, 417 E 68th St, New York, NY 10065, USA; Weill Cornell Medical College, New York, NY 10065, USA. Electronic address: sent@mskcc.org.
Memorial Sloan Kettering Cancer Center · USNagasaki University · JP
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MCoordinating center for the NCI small cell lung cancer research consortiumU24CA213274 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Lauren Averett Byers, JOHN D. MINNA · 2017 to 2026
$12.9MNovel therapeutic development for small cell lung cancerR35CA263816 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Charles M. Rudin · 2021 to 2026
$6.3MDeterminants of acquired resistance in small cell lung cancerR01CA197936 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI RUDIN, CHARLES M. · 2016 to 2020
$3.1MTargeting replication stress signaling to overcome immune evasion in small cell lung cancerR01CA258784 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SEN, TRIPARNA · 2021 to 2025
$2.4MAssessment of Tim-4+ Pleural Macrophages as Negative Regulators of Anti-Tumor T Cell Immunity in Lung CancerK08CA248723 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHOW, ANDREW · 2020 to 2022
$602kNCI NIH HHS K08 CA248723NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA197936NCI NIH HHS R01 CA258784NCI NIH HHS R35 CA263816NCI NIH HHS U24 CA213274
Abstract
Small cell lung cancers (SCLCs) have high mutational burden but are relatively unresponsive to immune checkpoint blockade (ICB). Using SCLC models, we demonstrate that inhibition of WEE1, a G2/M checkpoint regulator induced by DNA damage, activates the STING-TBK1-IRF3 pathway, which increases type I interferons (IFN-α and IFN-β) and pro-inflammatory chemokines (CXCL10 and CCL5), facilitating an immune response via CD8
Indexed as
Antineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenCell Cycle ProteinsLung NeoplasmsMembrane ProteinsProtein-Tyrosine KinasesSmall Cell Lung CarcinomaSTAT1 Transcription FactorAnimalsCell Line, TumorDrug SynergismImmune Checkpoint InhibitorsMiceProtein Kinase InhibitorsSTING ProteinB7-H1 AntigenCd274 protein, mouseCell Cycle ProteinsImmune Checkpoint InhibitorsMembrane ProteinsProtein Kinase InhibitorsProtein-Tyrosine KinasesStat1 protein, mouseSTAT1 Transcription FactorSting1 protein, mouseSTING ProteinWee1 protein, mouseCD8(+) T cellsCP: CancerCP: Immunologyimmune checkpoint blockadeimmunotherapyinterferonPD-L1SCLCSTAT1 pathwaySTING pathwayWEE1 inhibition
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.